Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05757349
Other study ID # TianjinMUEHhbj456
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 1, 2022
Est. completion date March 30, 2024

Study information

Verified date February 2023
Source Tianjin Medical University Eye Hospital
Contact Bojie Hu
Phone 13612130943
Email bhu07@tmu.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Idiopathic macular hole (IMH) is a fundus disease without clear etiology, most often seen in healthy women over 50 years of age, and is often associated with ocular manifestations such as loss of central vision and visual distortion. It is often associated with loss of central vision, visual distortion, and other ocular manifestations. It is currently treated by vitrectomy combined with internal limiting membranes (ILM) peeling followed by gas filling. A strict prone position for a certain period of time after surgery has a positive effect on the healing of the macular fissure. The need for a strict prone position after IMH has been demonstrated in previous studies (especially when the IMH diameter is >400 μm). However, due to the anti-human mechanics of the face-down position, patient comfort, sleep quality and quality of life are greatly compromised. Therefore, this study designed a smart head position monitoring device to assist patients in maintaining the correct position and recording the effective position time. The study was conducted to determine the shortest prone position time based on macular fissure closure, to minimize the adverse effects of postoperative position, and to obtain the maximum recovery of visual acuity and visual field.


Recruitment information / eligibility

Status Recruiting
Enrollment 86
Est. completion date March 30, 2024
Est. primary completion date March 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients aged 18 years or older; - Patients diagnosed with IMH; - Patients requiring face-down position after vitrectomy combined with ILM peeling and C3F8(14%) gas filling; Tolerated face-down position after surgery; - Agreed to the study protocol. Exclusion Criteria: - Myopia greater than or equal to -6.0 D; Eye axis length (AL) greater than 26.0mm; - Trauma, macular edema, macular degeneration, and other secondary MH with clear etiology; - Previous history of internal eye surgery in the operated eye; - Patients with local or systemic other diseases significantly affecting visual function; - Those who cannot maintain face-down position after surgery due to systemic factors, etc.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Face-down position time 1-day
Postoperative face-down position of subjects wearing the novel positioning sensor device for 1-day.
Face-down position time 3-day
Postoperative face-down position of subjects wearing the novel positioning sensor device for 3-day.

Locations

Country Name City State
China Tianjin medical university eye hosipital Tianjin Tianjin

Sponsors (1)

Lead Sponsor Collaborator
Tianjin Medical University Eye Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Macular hole closure rate Ratio of patients with postoperative lacunae that remained closed until the end of the follow-up time to the number of patients who reopened during the follow-up time of those who did not close after surgery 6 month postoperatively
Primary Effective face-down position time Novel positioning sensor related data cloud storage platform can record and extract effective face-down position time. 1 or 3 day postoperatively
Secondary Best corrected visual acuity change (BCVA) BCVA for patients after macular fissure surgery, expressed using the (ETDRS) Alphabet Chart. 1, 3, 6 month postoperatively
Secondary Retinal nerve fiber layer thickness change Three-dimensional spectral domain optical coherence tomography (SD-OCT) 1, 3, 6 month postoperatively
Secondary Macular ganglion cell complex thickness change (GCL+, GCL++) Three-dimensional spectral domain optical coherence tomography (SD-OCT) 1, 3, 6 month postoperatively
Secondary Mean retinal Sensitivity (MS) Micro Perimeter 3 1, 3, 6 month postoperatively
Secondary Central 2° and 4° fixation Micro Perimeter 3 1, 3, 6 month postoperatively
See also
  Status Clinical Trial Phase
Completed NCT02180633 - Unveiling Preclinical Idiopathic Macular Hole Formation N/A
Completed NCT02895594 - Outcome of Surgery for Idiopathic Macular Holes N/A
Completed NCT00941291 - Outcome of Idiopathic Macular Hole N/A
Completed NCT04683276 - ILM Inverted Flap Size in Macular Hole N/A
Recruiting NCT02905409 - Study of Surgery in Patients With Idiopathic Macular Hole Phase 4
Completed NCT00302328 - Trial of Prognostic Factors and Surgical Methods for the Treatment of Idiopathic Macular Holes N/A
Completed NCT00419185 - Indocyanine Green or Trypan Blue for Delamination of the Internal Limiting Membrane in Macular Hole Surgery N/A